Cargando…

NFKB1 Promoter DNA from nt+402 to nt+99 Is Hypomethylated in Different Human Immune Cells

Sepsis, with a persistently high 90-day mortality of about 46%, is the third most frequent cause of death in intensive care units worldwide. Further understanding of the inflammatory signaling pathways occurring in sepsis is important for new efficient treatment options. Key regulator of the inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Unterberg, Matthias, Kreuzer, Maxmiliane Julia, Schäfer, Simon Thomas, Bazzi, Zainab, Adamzik, Michael, Rump, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889142/
https://www.ncbi.nlm.nih.gov/pubmed/27249028
http://dx.doi.org/10.1371/journal.pone.0156702
_version_ 1782434952164409344
author Unterberg, Matthias
Kreuzer, Maxmiliane Julia
Schäfer, Simon Thomas
Bazzi, Zainab
Adamzik, Michael
Rump, Katharina
author_facet Unterberg, Matthias
Kreuzer, Maxmiliane Julia
Schäfer, Simon Thomas
Bazzi, Zainab
Adamzik, Michael
Rump, Katharina
author_sort Unterberg, Matthias
collection PubMed
description Sepsis, with a persistently high 90-day mortality of about 46%, is the third most frequent cause of death in intensive care units worldwide. Further understanding of the inflammatory signaling pathways occurring in sepsis is important for new efficient treatment options. Key regulator of the inflammatory response is the transcription factor NFκB. As we have recently shown, the -94 Ins/Del NFKB1 promoter polymorphism influences sepsis mortality. However, a molecular explanation is still missing. Thus, promoter activity might be varying depending on the NFKB1 genotype, explaining the genotype dependent mortality from sepsis, and one likely mechanism is the degree of promoter methylation. Therefore, we tested the hypothesis that NFκB mRNA expression is regulated by promoter methylation in human cell lines and primary immune cell cultures. First, we examined the methylation of the NFKB1 promoter in U937, REH and HL-60 cells. In the promoter region of nt+99/+229 methylation in all analyzed cell lines was below 1%. Following incubation with bacterial cell wall components, no significant changes in the frequency of promoter methylation in U937 and REH cells were measured and the methylation frequency was under 1%. However, NFκB1 mRNA expression was two-fold increased in U937 cells after 24 h incubation with LPS. By contrast, demethylation by 5-Aza-2′-deoxycytidine incubation enhanced NFκB1 expression significantly. In addition, we analyzed NFKB1 promoter methylation in primary cells from healthy volunteers depending on the NFKB1–94 Ins/Del genotype. Methylation in the promoter region from nt+402 to nt+99 was below 1%. Genotype dependent differences occurred in neutrophil cells, where DD-genotype was significantly more methylated compared to II genotype at nt+284/+402. Besides in the promoter region from nt-227/-8 in ID-genotypes methylation of neutrophils was significantly decreased compared to lymphocytes and in II-genotypes methylation in neutrophils was significantly decreased compared to lymphocytes and monocytes. In addition, CHART-PCR showed that the hypomethylated promoter regions are highly accessible. Therefore we assume that the demethylated regions are very important for NFKB1 promoter activity.
format Online
Article
Text
id pubmed-4889142
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48891422016-06-10 NFKB1 Promoter DNA from nt+402 to nt+99 Is Hypomethylated in Different Human Immune Cells Unterberg, Matthias Kreuzer, Maxmiliane Julia Schäfer, Simon Thomas Bazzi, Zainab Adamzik, Michael Rump, Katharina PLoS One Research Article Sepsis, with a persistently high 90-day mortality of about 46%, is the third most frequent cause of death in intensive care units worldwide. Further understanding of the inflammatory signaling pathways occurring in sepsis is important for new efficient treatment options. Key regulator of the inflammatory response is the transcription factor NFκB. As we have recently shown, the -94 Ins/Del NFKB1 promoter polymorphism influences sepsis mortality. However, a molecular explanation is still missing. Thus, promoter activity might be varying depending on the NFKB1 genotype, explaining the genotype dependent mortality from sepsis, and one likely mechanism is the degree of promoter methylation. Therefore, we tested the hypothesis that NFκB mRNA expression is regulated by promoter methylation in human cell lines and primary immune cell cultures. First, we examined the methylation of the NFKB1 promoter in U937, REH and HL-60 cells. In the promoter region of nt+99/+229 methylation in all analyzed cell lines was below 1%. Following incubation with bacterial cell wall components, no significant changes in the frequency of promoter methylation in U937 and REH cells were measured and the methylation frequency was under 1%. However, NFκB1 mRNA expression was two-fold increased in U937 cells after 24 h incubation with LPS. By contrast, demethylation by 5-Aza-2′-deoxycytidine incubation enhanced NFκB1 expression significantly. In addition, we analyzed NFKB1 promoter methylation in primary cells from healthy volunteers depending on the NFKB1–94 Ins/Del genotype. Methylation in the promoter region from nt+402 to nt+99 was below 1%. Genotype dependent differences occurred in neutrophil cells, where DD-genotype was significantly more methylated compared to II genotype at nt+284/+402. Besides in the promoter region from nt-227/-8 in ID-genotypes methylation of neutrophils was significantly decreased compared to lymphocytes and in II-genotypes methylation in neutrophils was significantly decreased compared to lymphocytes and monocytes. In addition, CHART-PCR showed that the hypomethylated promoter regions are highly accessible. Therefore we assume that the demethylated regions are very important for NFKB1 promoter activity. Public Library of Science 2016-06-01 /pmc/articles/PMC4889142/ /pubmed/27249028 http://dx.doi.org/10.1371/journal.pone.0156702 Text en © 2016 Unterberg et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Unterberg, Matthias
Kreuzer, Maxmiliane Julia
Schäfer, Simon Thomas
Bazzi, Zainab
Adamzik, Michael
Rump, Katharina
NFKB1 Promoter DNA from nt+402 to nt+99 Is Hypomethylated in Different Human Immune Cells
title NFKB1 Promoter DNA from nt+402 to nt+99 Is Hypomethylated in Different Human Immune Cells
title_full NFKB1 Promoter DNA from nt+402 to nt+99 Is Hypomethylated in Different Human Immune Cells
title_fullStr NFKB1 Promoter DNA from nt+402 to nt+99 Is Hypomethylated in Different Human Immune Cells
title_full_unstemmed NFKB1 Promoter DNA from nt+402 to nt+99 Is Hypomethylated in Different Human Immune Cells
title_short NFKB1 Promoter DNA from nt+402 to nt+99 Is Hypomethylated in Different Human Immune Cells
title_sort nfkb1 promoter dna from nt+402 to nt+99 is hypomethylated in different human immune cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889142/
https://www.ncbi.nlm.nih.gov/pubmed/27249028
http://dx.doi.org/10.1371/journal.pone.0156702
work_keys_str_mv AT unterbergmatthias nfkb1promoterdnafromnt402tont99ishypomethylatedindifferenthumanimmunecells
AT kreuzermaxmilianejulia nfkb1promoterdnafromnt402tont99ishypomethylatedindifferenthumanimmunecells
AT schafersimonthomas nfkb1promoterdnafromnt402tont99ishypomethylatedindifferenthumanimmunecells
AT bazzizainab nfkb1promoterdnafromnt402tont99ishypomethylatedindifferenthumanimmunecells
AT adamzikmichael nfkb1promoterdnafromnt402tont99ishypomethylatedindifferenthumanimmunecells
AT rumpkatharina nfkb1promoterdnafromnt402tont99ishypomethylatedindifferenthumanimmunecells